| Pharmaceutical Packaging, as a very active | | | | competition, restricted the development of |
| area of China's packaging branch, its constantly | | | | pharmaceutical packaging. |
| updated with the progress of the packaging industry | | | | In addition, the current drug bidding system has |
| has witnessed rapid development. China's accession to | | | | seriously hurt the enthusiasm of pharmaceutical |
| WTO, more international pharmaceutical companies | | | | manufacturers, enterprises can not make great effort |
| began to enter China, and in this regard intensified | | | | to reform the packaging, pharmaceutical packaging to |
| competition in China's pharmaceutical industry, it also | | | | keep old faces a long time. In addition, pharmaceutical |
| improves the quality and the industry technical | | | | packaging machinery equipment and materials, the |
| standards to drive the development of pharmaceutical | | | | technological level of backwardness is not strong |
| packaging has become a kind of inevitable. As the | | | | quality awareness of employees is also constrained |
| pharmaceutical industry and the people's daily lives, | | | | the development of China's pharmaceutical product |
| creating a pharmaceutical packaging specificity. | | | | packaging factors. |
| Therefore, in our country, the medical packaging | | | | Pharmaceutical Packaging Development Road |
| attributable to the State Food and Drug Supervision | | | | As China's health care system reform, medical |
| and Management areas. However, the technical level | | | | packaging disorder. Situation in backward fundamental |
| point of view, medical packaging and packaging printing | | | | change will occur. At present, China is constantly |
| relations are very large, concerned about the medical | | | | introducing and updating of medical packaging |
| packaging will become a kind of reasoning where one | | | | machinery and materials, pharmaceutical packaging |
| is based on the background, we were interviewed in | | | | industry will appear in a new situation. Drug types of |
| China Packaging Technology Association, packaging | | | | diversity, but also to bring about diversification in the |
| and printing, secretary general of Mr. Chen Qixiang and | | | | form of pharmaceutical packaging in recent years, |
| Shanghai Pharmaceutical Packaging Test Chi-wai, | | | | China's solid-type drugs, such as hormone tablets, |
| director of President, to the common interpretation of | | | | capsules, capsule, injection, medication packaging |
| domestic pharmaceutical packaging market. | | | | updates externally bonded very quickly, while |
| Pharmaceutical Packaging Status Perspective | | | | disposable plastic syringe the use of packaging and |
| At present, China's pharmaceutical companies | | | | application to the Chinese injection to bring a big |
| are mainly distributed in Jiangsu, Zhejiang and | | | | change, big infusion packages are also moving in the |
| Guangdong provinces, in terms of quantity and from | | | | direction of improved composite flexible packaging |
| the scale that Guangdong and Zhejiang in the vicinity | | | | bags and plastic bottles direction. |
| of pharmaceutical companies are dominant. From the | | | | Institute of Economic Research by the National |
| perspective of the development the past two years, | | | | Development and Reform Commission and the Beijing |
| pharmaceutical companies increasingly apparent | | | | Xinhua Online Information Technology Co., Ltd. jointly |
| large-scale production and grades, is gradually | | | | launched the "second quarter of 2003 the economy of |
| improving, the modern pharmaceutical companies a | | | | China Pharmaceutical Industry Analysis Report" shows |
| developing trend in the larger laboratories are equipped | | | | that by "SARS" the impact of the second quarter of |
| with their own packaging business. | | | | this year, production of various trades and professions |
| At present, high-speed, low efficiency. High | | | | medicine growth in the first place. From January to |
| consumption of extensive growth is the development | | | | June of this year, the pharmaceutical industry of |
| of China's pharmaceutical packaging typical | | | | industrial output 1433. S2 billion (current prices) over the |
| characteristics of domestic quality of the packaging of | | | | same period last year 21.55%; according to constant |
| pharmaceutical products in most grades low, and there | | | | price statistics, the pharmaceutical industrial output |
| are still a big gap between the developed countries. | | | | value of 183.09 billion yuan, an increase of 24.82%. In |
| This is evident from the following two data can be | | | | short, within the next few years look at the prospects |
| corroborated, Currently, there are less than 65:6 | | | | of China's development of Chinese medicine, can be |
| pharmaceutical packaging products to the international | | | | predicted that the future of pharmaceutical packaging |
| developed country on the 20th century, the age levels | | | | in China's rapid development. |
| of 0, the quality of packaging materials and packaging | | | | According to the U.S. Flexible Packaging |
| to the pharmaceutical industry's contribution rate is low. | | | | Association reported that, by 2003, the world of basic |
| In developed countries, medical packaging | | | | packaging needs of pharmaceutical products will have |
| pharmaceuticals accounted for the value of 30:6, while | | | | 4.2% growth in total output value will reach 11.2 billion |
| the proportion of China's less than 10%. At present, for | | | | U.S. dollars in the next five years, the medical |
| the domestic large-scale pharmaceutical packaging | | | | packaging will become the second largest flexible |
| businesses in the device compared with foreign | | | | packaging industry, economic growth. To seize this |
| countries, the gap is not, but in the software | | | | opportunity, experts believe that China's |
| environment is very unsatisfactory. | | | | Pharmaceutical Packaging should do the following: First, |
| It is understood that the reason for this | | | | promote the use of drugs to speed up Liquid Plastic |
| difference mainly in three aspects: first, a lower overall | | | | containers; second, accelerate the development of |
| level of China's pharmaceutical industry, pharmaceutical | | | | Chinese medicine plastic hollow container packaging, |
| manufacturers the technology is relatively backward. | | | | should be more used to HDPE, PP, PET, PEN and |
| From the size of pharmaceutical companies, China's | | | | other materials, and using injection blow molding |
| pharmaceutical enterprises in number, repeat the | | | | process such as production of hollow plastic |
| process on a serious drugs, pharmaceuticals low level | | | | containers. In the hollow container mouth using |
| of corporate governance. Second, China's | | | | electromagnetic induction aluminum foil sealing gasket in |
| pharmaceutical packaging industry-related regulations | | | | order to enhance the safety of drug protection; the |
| and technical standards behind. | | | | same time, promote the use of Chinese medicine to |
| At present, China has gradually introduced the | | | | speed up the plastic composite film bag. |
| pharmaceutical industry specification standard system, | | | | It should be said, pharmaceutical packaging in |
| but there are still some distance from the international | | | | the next few years will see rapid development, the |
| standard. Industry-standard system for packaging of | | | | prospects for good, a large space. After single-dose |
| pharmaceutical products due to the absence of both | | | | packaging of drugs, more and more overseas |
| good and bad situation. Finally, drug distribution system | | | | pharmaceutical companies have begun to flood the |
| plagued by problems. The long-term sales of | | | | Chinese market, how to seize this opportunity of |
| pharmaceutical products to hospitals mainly in | | | | China's pharmaceutical packaging business worth |
| pharmacies sell drugs only a small part of the total, | | | | consideration. |
| which limited the drug directly involved in market | | | | |